(Image source: Photo.com)
Recently, Suzhou Zhihe Biomedical Technology Co., Ltd. (hereinafter referred to as "Zhihe Bio") announced the completion of nearly 100 million yuan in C+ round of financing.This round of financing was led by Oriza Holdings, followed by Yuzhi Capital, Jiansu Capital, and Suzhou Leading Venture Capital, and continued to be supported by the old shareholder Ruihe Capital.
The funds raised in this round will provide financial support for the commercialization of the company's first product to be marketed, human thyroid-stimulating hormone injection (rhTSH, trade name Zhishujia ®), clinical trials of innovative radiodiagnostic drugs such as SNA002, and IND promotion of new target therapeutic nuclear drugs such as SNA014 and SNA025.
According to the data of Qichamao, Suzhou Zhihe Biomedical Technology Co., Ltd. was established in 2015 with a registered capital of 1,864,729 yuan, and its business scope includes technology development in the fields of biotechnology, medicine and medical devices.
Since 2023, the rapid ramp-up of diagnostic nuclear drug companies Telix, Lantheus, etc., as well as the therapeutic nuclear drug company Novartis, shows the continuous growth of demand for nuclear drugs at the clinical end. Multinational companies such as Lilly, BMS and A-Z have increased their investment in the field of nuclear medicine through mergers and acquisitions of nearly 10 billion US dollars, indicating that nuclear medicine is becoming one of the hottest spots in the global pharmaceutical industry.
Nuclear medicine generally refers to radiopharmaceuticals and is usually used for radiotherapy or radiodiagnostic purposes. These drugs contain radioactive isotopes that can be used to treat cancer, thyroid disease, bone disease, etc. Nuclear drugs have important application value in medicine, but they need to be strictly controlled and managed to ensure safe use. The successful financing of Zhinulei also reflects investors' confidence and optimism in the nuclear medicine field.
- Classification of radiopharmaceuticals
Similar to general drugs, radiopharmaceuticals need to meet the requirements of pharmacopoeia, such as sterility, no pyrogenic, low chemical toxicity, etc., in addition, there are certain requirements for the type, energy and radioactive half-life of the nuclear rays emitted according to the needs of diagnosis and treatment.
Radiopharmaceuticals are divided into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals according to their uses, among which diagnostic radiopharmaceuticals can be further divided into single-photon radiopharmaceuticals and positron radiopharmaceuticals.
-- Policies support the development of radiopharmaceuticals
The radiopharmaceutical industry in mainland China has received strong policy support to promote its sustained and rapid development. For example, in March 2017, the State Council recently revised the Measures for the Administration of Radiopharmaceuticals, which clarified that the production and operation of radiopharmaceuticals from R&D to sales are directly supervised by the State Council, and the high-intensity and high-density supervision and licensing requirements have greatly improved the standardization of China's radiopharmaceutical industry and promoted the healthy development of the industry.
Although China's radiopharmaceutical industry started late and the market penetration rate is not high, with the continuous progress of medical technology and the country's attention to the medical and health industry, the development prospects of the radiopharmaceutical industry are still very broad. With the improvement of people's requirements for medical level and service quality, as well as the increasing number of diseases such as cancer, the demand for radiopharmaceuticals in diagnosis and treatment will gradually increase, and it is expected that China's radiopharmaceutical industry is expected to usher in rapid development and become an important part of the medical and health industry.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "Analysis Report on Market Prospect and Investment Strategic Planning of China's Pharmaceutical Industry" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certification, IPO consulting/fundraising feasibility study, IPO working paper consulting, etc. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers. More enterprise data, enterprise information, and enterprise development are all in the [Qichamao APP], the most cost-effective and most comprehensive enterprise query platform.